Community Healthcare Trust (CHCT) 10-Q 3 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 27, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-37401
Entity Registrant Name	Community Healthcare Trust Inc
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	46-5212033
Entity Address, Address Line One	3326 Aspen Grove Drive
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	771-3052
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	CHCT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		25,072,355
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001631569
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Real estate properties
Land and land improvements	$ 98,561	$ 97,397
Buildings, improvements, and lease intangibles	741,969	736,465
Personal property	225	223
Total real estate properties	840,755	834,085
Less accumulated depreciation	(140,985)	(133,056)
Total real estate properties, net	699,770	701,029
Cash and cash equivalents	1,178	2,351
Restricted cash	521	516
Other assets, net	59,761	50,337
Total assets	761,230	754,233
Liabilities
Debt, net	269,670	265,625
Accounts payable and accrued liabilities	6,894	7,845
Other liabilities, net	13,552	18,651
Total liabilities	290,116	292,121
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.01 par value; 450,000 shares authorized; 25,072 and 24,983 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	251	250
Additional paid-in capital	597,548	595,624
Cumulative net income	64,647	59,123
Accumulated other comprehensive income (loss)	7,542	(4,980)
Cumulative dividends	(198,874)	(187,905)
Total stockholders’ equity	471,114	462,112
Total liabilities and stockholders' equity	$ 761,230	$ 754,233

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized (in shares)	450,000,000	450,000,000
Common Stock, shares issued (in shares)	25,072,000	24,983,000
Common Stock, shares outstanding (in shares)	25,072,000	24,983,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUES
Rental income	$ 22,604	$ 20,780
Other operating interest	877	615
Total revenue	23,481	21,395
EXPENSES
Property operating	4,091	3,729
General and administrative	3,316	2,859
Depreciation and amortization	7,942	7,225
Total expenses	15,349	13,813
INCOME BEFORE INCOME TAXES AND OTHER ITEMS	8,132	7,582
Interest expense	(2,626)	(2,229)
Deferred income tax benefit (expense)	17	(39)
Interest and other income	1	1
Net income	$ 5,524	$ 5,315
NET INCOME PER COMMON SHARE:
Net income per common share – Basic (in dollars per share)	$ 0.21	$ 0.21
Net income per common share – Diluted (in dollars per share)	$ 0.21	$ 0.21
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC (in shares)	23,570	22,809
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED (in shares)	23,570	22,809

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 5,524	$ 5,315
Other comprehensive income:
Increase in fair value of cash flow hedges	11,407	2,803
Reclassification for amounts recognized as interest expense	1,115	932
Total other comprehensive income	12,522	3,735
COMPREHENSIVE INCOME	$ 18,046	$ 9,050

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid in Capital	Cumulative Net Income	Accumulated Other Comprehensive (Loss) Income	Cumulative Dividends
Beginning balance (in shares) at Dec. 31, 2020		0	23,888
Beginning balance at Dec. 31, 2020	$ 429,916	$ 0	$ 239	$ 550,391	$ 36,631	$ (11,846)	$ (145,499)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)			435
Stock issuance costs	19,845		$ 4	19,841
Stock-based compensation (in shares)			94
Stock-based compensation	1,550		$ 1	1,549
Unrecognized gain on cash flow hedges	2,803					2,803
Reclassification adjustment for losses included in net income (interest expense)	932					932
Net income	5,315				5,315
Dividends to common stockholders	(10,275)						(10,275)
Ending balance (in shares) at Mar. 31, 2021		0	24,417
Ending balance at Mar. 31, 2021	450,086	$ 0	$ 244	571,781	41,946	(8,111)	(155,774)
Beginning balance (in shares) at Dec. 31, 2020		0	23,888
Beginning balance at Dec. 31, 2020	$ 429,916	$ 0	$ 239	550,391	36,631	(11,846)	(145,499)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)	823
Ending balance (in shares) at Dec. 31, 2021		0	24,983
Ending balance at Dec. 31, 2021	$ 462,112	$ 0	$ 250	595,624	59,123	(4,980)	(187,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)	0
Stock issuance costs	$ (197)			(197)
Stock-based compensation (in shares)			89
Stock-based compensation	2,122		$ 1	2,121
Unrecognized gain on cash flow hedges	11,407					11,407
Reclassification adjustment for losses included in net income (interest expense)	1,115					1,115
Net income	5,524				5,524
Dividends to common stockholders	(10,969)						(10,969)
Ending balance (in shares) at Mar. 31, 2022		0	25,072
Ending balance at Mar. 31, 2022	$ 471,114	$ 0	$ 251	$ 597,548	$ 64,647	$ 7,542	$ (198,874)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cumulative Dividends
Dividends to common stockholders, per share (in dollars per share)	$ 0.4375	$ 0.4275

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
OPERATING ACTIVITIES
Net income	$ 5,524	$ 5,315
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,942	7,225
Other amortization	216	229
Stock-based compensation	2,122	1,550
Straight-line rent receivable	(820)	(838)
Deferred income tax (benefit) expense	(17)	39
Changes in operating assets and liabilities:
Other assets	(844)	(291)
Accounts payable and accrued liabilities	352	(820)
Other liabilities	(73)	1,084
Net cash provided by operating activities	14,402	13,493
INVESTING ACTIVITIES
Acquisitions of real estate	(5,845)	(60,007)
Acquisition and funding of notes receivable	(1,500)	(7,110)
Proceeds from the repayment of notes receivable	750	890
Capital expenditures on existing real estate properties	(1,892)	(1,045)
Net cash used in investing activities	(8,487)	(67,272)
FINANCING ACTIVITIES
Net borrowings (repayments) on revolving credit facility	4,000
Net borrowings (repayments) on revolving credit facility		(26,000)
Term loan borrowings	0	125,000
Term loan repayments	0	(50,000)
Mortgage note repayments	(40)	(29)
Dividends paid	(10,969)	(10,275)
Proceeds from issuance of common stock	0	19,919
Equity issuance costs	(74)	(76)
Debt issuance costs	0	(1,649)
Net cash (used in) provided by financing activities	(7,083)	56,890
(Decrease) increase in cash and cash equivalents and restricted cash	(1,168)	3,111
Cash and cash equivalents and restricted cash, beginning of period	2,867	2,892
Cash and cash equivalents and restricted cash, end of period	1,699	6,003
Supplemental Cash Flow Information:
Interest paid	2,476	2,105
Invoices accrued for construction, tenant improvement and other capitalized costs	982	1,591
Reclassification of registration statement costs incurred in prior year to equity issuance costs	119	81
Increase in fair value of cash flow hedges	11,407	2,803
Income taxes paid	12	25
Capitalized interest	$ 228	$ 37

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Business Overview Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of March 31, 2022, the Company had investments of approximately $843.8 million in 158 real estate properties (including a portion of one property accounted for as a financing lease with a gross amount totaling approximately $3.0 million). The properties are located in 34 states, totaling approximately 3.4 million square feet in the aggregate and were approximately 89.9% leased at March 31, 2022 with a weighted average remaining lease term of approximat ely 7.6 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the condensed consolidated financial statements, are outside the scope of our independent registered public accounting firm's review. Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2022. All material intercompany accounts and transactions have been eliminated. Use of Estimates in the Condensed Consolidated Financial Statements Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may materially differ from those estimates. Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of March 31, (Dollars in thousands) 2022 2021 Cash and cash equivalents $ 1,178 $ 5,605 Restricted cash 521 398 Cash, cash equivalents and restricted cash $ 1,699 $ 6,003 Income Taxes The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes. No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company also evaluates the realizability of its deferred tax assets and will record valuation allowances if it is determined that more likely than not the asset will not be recovered. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with generally accepted accounting principles) and meet other requirements to continue to qualify as a REIT. New Accounting Pronouncements Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Real Estate Properties

Real Estate Properties	3 Months Ended
	Mar. 31, 2022
Real Estate [Abstract]
Real Estate Properties	Real Estate Properties As of March 31, 2022, we had investments of approximately $843.8 million in 158 real estate properties (including a portion of one property accounted for as a financing lease with a gross amount totaling approximately $3.0 million). In addition to the Company's two acquisitions during the three months ended March 31, 2022, the property count as of March 31, 2022 was increased due to the breakout of three properties previously included within the property count of two other buildings, thereby increasing the property count by five for the quarter. The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables: Property Type # of Properties Gross Investment Medical Office Building 65 $ 297,138 Acute Inpatient Behavioral 5 130,367 Inpatient Rehabilitation Facilities 6 127,676 Specialty Centers 34 106,169 Physician Clinics 29 81,988 Surgical Centers and Hospitals 10 54,518 Behavioral Specialty Facilities 8 30,978 Long-term Acute Care Hospitals 1 14,937 Total 158 $ 843,771 State # of Properties Gross Investment Texas 15 $ 136,953 Illinois 16 120,172 Ohio 22 77,230 Florida 14 66,037 Massachusetts 2 35,298 All Others 89 408,081 Total 158 $ 843,771 Primary Tenant # of Properties Gross Investment US Healthvest 3 $ 77,964 Everest Rehabilitation 3 57,100 All Others 152 708,707 Total 158 $ 843,771

Real Estate Leases

Real Estate Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Real Estate Leases	Real Estate Leases Lessor Accounting The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2039. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease. Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of March 31, 2022, are as follows (in thousands): 2022 (nine months ending December 31) $ 57,145 2023 72,288 2024 73,219 2025 62,603 2026 55,044 2027 and thereafter 339,736 $ 660,035 Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent included in rental income was approximately $0.8 million and $0.8 million, respectively, for the three months ended March 31, 2022 and 2021. Purchase Option Provisions Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At March 31, 2022, the Company had an aggregate gross investment of approximately $25.2 million in four real estate properties with purchase options exercisable at March 31, 2022 that had not been exercised. Sales-type lease The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of March 31, 2022, are as follows (in thousands): 2022 (nine months ended December 31) $ 246 2023 336 2024 346 2025 356 2026 367 2027 and thereafter 5,587 Total undiscounted lease receivable 7,238 Discount (4,206) Lease receivable $ 3,032 During the three months ended March 31, 2022 and 2021, the Company recognized interest income of approximately $0.1 million and $0.1 million, respectively, related to this lease which is included in other operating interest on the Company's Consolidated Income Statements. Lessee Accounting At March 31, 2022, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and one non-prepaid ground lease accounted for as a financing lease with an expiration date through 2085, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2022 (nine months ended December 31) $ 31 $ 94 2023 42 125 2024 43 138 2025 44 138 2026 44 138 2027 and thereafter 1,193 5,483 Total undiscounted lease payments 1,397 6,116 Discount (604) (3,144) Lease liabilities $ 793 $ 2,972 The following table discloses other information regarding the ground leases. Three Months Ended 2022 2021 Operating leases: Weighted-average remaining lease term in years (including renewal options) 36.73 37.97 Weighted-average discount rate 4.0 % 4.0 % Financing leases: Weighted-average remaining lease term in years (including renewal options) 36.75 n/a Weighted-average discount rate 4.1 % n/a

Real Estate Acquisitions

Real Estate Acquisitions	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Real Estate Acquisitions	Real Estate Acquisitions During the first quarter of 2022, the Company acquired two real estate properties. Upon acquisition, the properties were 100% leased in the aggregate with lease expi rations through 2028 . Amoun ts reflected in revenues and net income for these properties for the three months ended March 31, 2022 were approximately $45,000 and a $5,000 loss, respectively, and transaction costs totaling approximately $0.1 million were capitalized relating to these property acquisitions. Location Property Type (1) Date Purchase Cash Real Estate Other Square Footage (000's) (000's) (000's) (000's) Toledo, OH MOB 03/09/22 $ 2,606 $ 2,621 $ 2,735 $ (114) 17,465 Fremont, NE MOB 03/09/22 3,232 3,224 3,443 (219) 12,850 $ 5,838 $ 5,845 $ 6,178 $ (333) 30,315 (1) MOB - Medical Office Building The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the three months ended March 31, 2022. Relative Estimated (in thousands) (in years) Land and land improvements $ 1,123 6.2 Building and building improvements 3,868 20.5 Intangibles: At-market lease intangibles 1,187 4.5 Below-market lease intangibles (194) 6.1 Total intangibles 993 Accounts payable, accrued liabilities and other liabilities assumed (97) Prorated rent, interest and operating expense reimbursement amounts collected (42) Total cash consideration $ 5,845

Debt, net

Debt, net	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt, net	Debt, net The table below details the Company's debt as of March 31, 2022 and December 31, 2021. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Maturity Dates Credit Facility: Revolving Credit Facility $ 16,000 $ 12,000 3/26 A-2 Term Loan, net 49,833 49,813 3/24 A-3 Term Loan, net 74,518 74,487 3/26 A-4 Term Loan, net 124,324 124,296 3/28 Mortgage Note Payable, net 4,995 5,029 5/24 $ 269,670 $ 265,625 On March 19, 2021, Community Healthcare Trust Incorporated, as borrower, entered into a third amended and restated credit facility by and among Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent (the "Credit Facility"). The Credit Facility allows the Company to borrow, through the accordion feature, up to $600.0 million, including the ability to add and fund incremental term loans, and provides the Company the ability to apply lower margins to its annual interest rate after it obtains an investment grade rating of BBB-/Baa3 (or the equivalent) from a rating agency, and modified its debt covenants. The Credit Facility provides for a $150.0 million Revolving Credit Facility and $250.0 million in term loans (the "Term Loans"). The Revolving Credit Facility matures on March 19, 2026 and includes one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $50.0 million (the "A-2 Term Loan"), which matures on March 29, 2024, a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which matures on March 29, 2026, and a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan), which matures on March 19, 2028. Amounts outstanding under the Revolving Credit Facility bear annual interest at a floating rate that is based, at the Company’s option, on either: (i) LIBOR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. The Company had $16.0 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 3.0% and a borrowing capacity remaining of $134.0 million at March 31, 2022. Amounts outstanding under the Term Loans, as amended, bear annual interest at a floating rate that is based, at the Company’s option, on either: (i) LIBOR plus 1.45% to 2.30% or (ii) a base rate plus 0.45% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 for more details on the interest rate swaps. At March 31, 2022, the Company had $250.0 million outstanding under the Term Loans which had a fixed weighted average interest rate under the swaps of approximate ly 3.79% . The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments Risk Management Objective of Using Derivatives The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations. Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2022, the Company had twelve outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $250.0 million. Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021. Asset Derivatives Fair Value at Liability Derivatives Fair Value at (Dollars in thousands) March 31, 2022 December 31, 2021 Balance Sheet Classification March 31, 2022 December 31, 2021 Balance Sheet Classification Interest rate swaps $ 7,645 $ 343 Other assets, net $ 103 $ 5,324 Other liabilities, net The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive loss ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $5,200 will be reclassified from AOCI as a decrease to interest expense. Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three months ended March 31, 2022 and 2021. Three Months Ended (Dollars in thousands) 2022 2021 Amount of unrealized gain recognized in OCI on derivatives $ 11,407 $ 2,803 Amount of loss reclassified from AOCI into interest expense $ 1,115 $ 932 Total interest expense presented in the Condensed Consolidated Statements of Income in which the effects of the cash flow hedges are recorded $ 2,626 $ 2,229 Tabular Disclosures of Offsetting Derivatives The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of March 31, 2022 and December 31, 2021. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets. Offsetting of Derivative Assets (as of March 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 7,645 $ — $ 7,645 $ (103) $ — $ 7,542 Offsetting of Derivative Liabilities (as of March 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ (103) $ — $ (103) $ 103 $ — $ — Offsetting of Derivative Assets (as of December 31, 2021) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 343 $ — $ 343 $ (247) $ — $ 96 Offsetting of Derivative Liabilities (as of December 31, 2021) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ (5,324) $ — $ (5,324) $ 247 $ — $ (5,077) Credit-risk-related Contingent Features As of March 31, 2022, the Company did not have any derivatives in a net liability position. As of March 31, 2022, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock The following table provides a reconciliation of the beginning and ending common stock balances for the three months ended March 31, 2022 and for the year ended December 31, 2021: (In thousands) Three Months Ended Year Ended Balance, beginning of period 24,983 23,888 Issuance of common stock — 823 Restricted stock issued 92 273 Restricted stock forfeited (3) (1) Balance, end of period 25,072 24,983 ATM Program The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC., as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $360.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law. The Company elected not to issue any shares under the ATM Program during the three months ended March 31, 2022. As of March 31, 2022, the Company had approximat ely $101.0 million re maining that may be issued under the ATM Program.

Net Income Per Common Share

Net Income Per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income Per Common Share	Net Income Per Common Share The following table sets forth the computation of basic and diluted net income per common share for the three months ended March 31, 2022 and 2021, respectively. Three Months Ended (In thousands, except per share data) 2022 2021 Net income $ 5,524 $ 5,315 Participating securities' share in earnings (658) (538) Net income, less participating securities' share in earnings $ 4,866 $ 4,777 Weighted average Common Shares outstanding Weighted average Common Shares outstanding 25,060 24,053 Unvested restricted shares (1,490) (1,244) Weighted average Common Shares outstanding–Basic 23,570 22,809 Dilutive potential common shares — — Weighted average Common Shares outstanding –Diluted 23,570 22,809 Basic Net Income per Common Share $ 0.21 $ 0.21 Diluted Net Income per Common Share $ 0.21 $ 0.21

Stock Incentive Plan

Stock Incentive Plan	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock Incentive Plan	Stock Incentive Plan A summary of the activity under the Company's 2014 Incentive Plan, as amended, for the three months ended March 31, 2022 and 2021 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods. Three Months Ended (Dollars and shares in thousands) 2022 2021 Stock-based awards, beginning of period 1,416 1,165 Stock in lieu of compensation 44 44 Stock awards 48 49 Total stock granted 92 93 Vested shares (5) — Forfeited shares (1) — Stock-based awards, end of period 1,502 1,258 Amortization expense $ 2,122 $ 1,558

Other Assets, net

Other Assets, net	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets, net	Other Assets, net Other assets, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are detailed in the table below. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Notes receivable $ 26,750 $ 26,000 Accounts and interest receivable 2,741 2,116 Straight-line rent receivable 12,806 11,968 Prepaid assets 749 701 Deferred financing costs, net 843 896 Leasing commissions, net 1,249 1,239 Deferred tax assets, net 365 348 Fair value of interest rate swaps 7,645 343 Above-market lease intangible assets, net 557 611 Sales-type lease receivable 3,032 3,031 Financing right-of-use asset 1,857 1,870 Operating lease right-of-use assets 781 788 Other 386 426 $ 59,761 $ 50,337 The Company's notes receivable mainly included: • At March 31, 2022 and December 31, 2021, notes receivable included a $11.3 million and $12.0 million, respectively, term loan, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum. • At March 31, 2022, notes receivable included a $6.0 million term loan and a $9.5 million revolving credit facility, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. The term loan bears interest at 9% per annum, with interest only payments due for the first year and then equal monthly installments of principal payments due beginning June 30, 2022. The term loan facility matures on July 1, 2027. The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025. In addition, the Company has committed to fund, at the Company’s discretion, additional amounts, up to $5.0 million with interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note. The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable. The VIEs that we have identified at March 31, 2022 are summarized in the table below. Classification Carrying Amount (in thousands) Maximum Exposure to Loss (in thousands) Note receivable (term loan) $ 11,250 $ 11,250 Note receivable (revolving credit facility) $ 9,500 $ 9,500 Note receivable (term loan) $ 6,000 $ 6,000

Other Liabilities, net

Other Liabilities, net	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities, net	Other Liabilities, net Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are detailed in the table below. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Prepaid rent $ 3,860 $ 3,791 Security deposits 4,610 4,640 Below-market lease intangibles, net 768 616 Fair value of derivatives 103 5,324 Financing lease liability 2,972 2,973 Operating lease liability 793 795 Other 446 512 $ 13,552 $ 18,651

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value. Cash and cash equivalents and restricted cash - The carrying amount approximates the fair value. Notes receivable - The fair value is estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and are classified as level 2 in the hierarchy. Borrowings under our Credit Facility - The carrying amount approximates the fair value because the borrowings are based on variable market interest rates. Derivative financial instruments - The fair value is estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs are utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps are observable in active markets and are classified as level 2 in the hierarchy. Mortgage note payable - The fair value is estimated using cash flow analyses which are based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and are classified as level 2 in the hierarchy. The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at March 31, 2022 and December 31, 2021, using level 2 inputs. March 31, 2022 December 31, 2021 (Dollars in thousands) Carrying Value Fair Value Carrying Value Fair Value Notes receivable $ 26,750 $ 26,152 $ 26,000 $ 25,869 Interest rate swap asset $ 7,645 $ 7,645 $ 343 $ 343 Interest rate swap liability $ 103 $ 103 $ 5,324 $ 5,324 Mortgage note payable (principal amount) $ 5,036 $ 4,965 $ 5,076 $ 5,129

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Dividend Declared On April 28, 2022, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.44 per share. The dividend is payable on May 27, 2022 to stockholders of record on May 13, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2022. All material intercompany accounts and transactions have been eliminated.
Use of Estimates in the Condensed Consolidated Financial Statements	Use of Estimates in the Condensed Consolidated Financial Statements Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may materially differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents and Restricted CashCash and cash equivalents includes short-term investments with original maturities of three months or less when purchased.
Restricted Cash	Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments.
Income Taxes	Income Taxes The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes.
New Accounting Pronouncements	New Accounting Pronouncements Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Restrictions on cash and cash equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of March 31, (Dollars in thousands) 2022 2021 Cash and cash equivalents $ 1,178 $ 5,605 Restricted cash 521 398 Cash, cash equivalents and restricted cash $ 1,699 $ 6,003
Schedule of cash and cash equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of March 31, (Dollars in thousands) 2022 2021 Cash and cash equivalents $ 1,178 $ 5,605 Restricted cash 521 398 Cash, cash equivalents and restricted cash $ 1,699 $ 6,003

Real Estate Properties (Tables)

Real Estate Properties (Tables)	3 Months Ended
	Mar. 31, 2022
Real Estate [Abstract]
Schedule of real estate property investments	The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables: Property Type # of Properties Gross Investment Medical Office Building 65 $ 297,138 Acute Inpatient Behavioral 5 130,367 Inpatient Rehabilitation Facilities 6 127,676 Specialty Centers 34 106,169 Physician Clinics 29 81,988 Surgical Centers and Hospitals 10 54,518 Behavioral Specialty Facilities 8 30,978 Long-term Acute Care Hospitals 1 14,937 Total 158 $ 843,771 State # of Properties Gross Investment Texas 15 $ 136,953 Illinois 16 120,172 Ohio 22 77,230 Florida 14 66,037 Massachusetts 2 35,298 All Others 89 408,081 Total 158 $ 843,771 Primary Tenant # of Properties Gross Investment US Healthvest 3 $ 77,964 Everest Rehabilitation 3 57,100 All Others 152 708,707 Total 158 $ 843,771

Real Estate Leases (Tables)

Real Estate Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of future minimum lease payments for operating leases	Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of March 31, 2022, are as follows (in thousands): 2022 (nine months ending December 31) $ 57,145 2023 72,288 2024 73,219 2025 62,603 2026 55,044 2027 and thereafter 339,736 $ 660,035
Sales-type maturity	Future lease payments due to the Company under this lease for the years ending December 31, as of March 31, 2022, are as follows (in thousands): 2022 (nine months ended December 31) $ 246 2023 336 2024 346 2025 356 2026 367 2027 and thereafter 5,587 Total undiscounted lease receivable 7,238 Discount (4,206) Lease receivable $ 3,032
Schedule of operating lease payments	The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2022 (nine months ended December 31) $ 31 $ 94 2023 42 125 2024 43 138 2025 44 138 2026 44 138 2027 and thereafter 1,193 5,483 Total undiscounted lease payments 1,397 6,116 Discount (604) (3,144) Lease liabilities $ 793 $ 2,972
Schedule of finance lease payments	The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2022 (nine months ended December 31) $ 31 $ 94 2023 42 125 2024 43 138 2025 44 138 2026 44 138 2027 and thereafter 1,193 5,483 Total undiscounted lease payments 1,397 6,116 Discount (604) (3,144) Lease liabilities $ 793 $ 2,972
Ground leases	The following table discloses other information regarding the ground leases. Three Months Ended 2022 2021 Operating leases: Weighted-average remaining lease term in years (including renewal options) 36.73 37.97 Weighted-average discount rate 4.0 % 4.0 % Financing leases: Weighted-average remaining lease term in years (including renewal options) 36.75 n/a Weighted-average discount rate 4.1 % n/a

Real Estate Acquisitions (Table

Real Estate Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of acquisitions	Location Property Type (1) Date Purchase Cash Real Estate Other Square Footage (000's) (000's) (000's) (000's) Toledo, OH MOB 03/09/22 $ 2,606 $ 2,621 $ 2,735 $ (114) 17,465 Fremont, NE MOB 03/09/22 3,232 3,224 3,443 (219) 12,850 $ 5,838 $ 5,845 $ 6,178 $ (333) 30,315 (1) MOB - Medical Office Building
Schedule of assets acquired and liabilities assumed	The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the three months ended March 31, 2022. Relative Estimated (in thousands) (in years) Land and land improvements $ 1,123 6.2 Building and building improvements 3,868 20.5 Intangibles: At-market lease intangibles 1,187 4.5 Below-market lease intangibles (194) 6.1 Total intangibles 993 Accounts payable, accrued liabilities and other liabilities assumed (97) Prorated rent, interest and operating expense reimbursement amounts collected (42) Total cash consideration $ 5,845

Debt, net (Tables)

Debt, net (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of debt	The table below details the Company's debt as of March 31, 2022 and December 31, 2021. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Maturity Dates Credit Facility: Revolving Credit Facility $ 16,000 $ 12,000 3/26 A-2 Term Loan, net 49,833 49,813 3/24 A-3 Term Loan, net 74,518 74,487 3/26 A-4 Term Loan, net 124,324 124,296 3/28 Mortgage Note Payable, net 4,995 5,029 5/24 $ 269,670 $ 265,625

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments on balance sheet	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021. Asset Derivatives Fair Value at Liability Derivatives Fair Value at (Dollars in thousands) March 31, 2022 December 31, 2021 Balance Sheet Classification March 31, 2022 December 31, 2021 Balance Sheet Classification Interest rate swaps $ 7,645 $ 343 Other assets, net $ 103 $ 5,324 Other liabilities, net Offsetting of Derivative Assets (as of March 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 7,645 $ — $ 7,645 $ (103) $ — $ 7,542 Offsetting of Derivative Liabilities (as of March 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ (103) $ — $ (103) $ 103 $ — $ — Offsetting of Derivative Assets (as of December 31, 2021) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 343 $ — $ 343 $ (247) $ — $ 96 Offsetting of Derivative Liabilities (as of December 31, 2021) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ (5,324) $ — $ (5,324) $ 247 $ — $ (5,077)
Schedule of derivative gain (loss)	The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three months ended March 31, 2022 and 2021. Three Months Ended (Dollars in thousands) 2022 2021 Amount of unrealized gain recognized in OCI on derivatives $ 11,407 $ 2,803 Amount of loss reclassified from AOCI into interest expense $ 1,115 $ 932 Total interest expense presented in the Condensed Consolidated Statements of Income in which the effects of the cash flow hedges are recorded $ 2,626 $ 2,229

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of reconciliation of common stock	The following table provides a reconciliation of the beginning and ending common stock balances for the three months ended March 31, 2022 and for the year ended December 31, 2021: (In thousands) Three Months Ended Year Ended Balance, beginning of period 24,983 23,888 Issuance of common stock — 823 Restricted stock issued 92 273 Restricted stock forfeited (3) (1) Balance, end of period 25,072 24,983

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of earnings per share	The following table sets forth the computation of basic and diluted net income per common share for the three months ended March 31, 2022 and 2021, respectively. Three Months Ended (In thousands, except per share data) 2022 2021 Net income $ 5,524 $ 5,315 Participating securities' share in earnings (658) (538) Net income, less participating securities' share in earnings $ 4,866 $ 4,777 Weighted average Common Shares outstanding Weighted average Common Shares outstanding 25,060 24,053 Unvested restricted shares (1,490) (1,244) Weighted average Common Shares outstanding–Basic 23,570 22,809 Dilutive potential common shares — — Weighted average Common Shares outstanding –Diluted 23,570 22,809 Basic Net Income per Common Share $ 0.21 $ 0.21 Diluted Net Income per Common Share $ 0.21 $ 0.21

Stock Incentive Plan (Tables)

Stock Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of nonvested restricted stock activity	A summary of the activity under the Company's 2014 Incentive Plan, as amended, for the three months ended March 31, 2022 and 2021 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods. Three Months Ended (Dollars and shares in thousands) 2022 2021 Stock-based awards, beginning of period 1,416 1,165 Stock in lieu of compensation 44 44 Stock awards 48 49 Total stock granted 92 93 Vested shares (5) — Forfeited shares (1) — Stock-based awards, end of period 1,502 1,258 Amortization expense $ 2,122 $ 1,558

Other Assets, net (Tables)

Other Assets, net (Tables)	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other assets	Other assets, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are detailed in the table below. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Notes receivable $ 26,750 $ 26,000 Accounts and interest receivable 2,741 2,116 Straight-line rent receivable 12,806 11,968 Prepaid assets 749 701 Deferred financing costs, net 843 896 Leasing commissions, net 1,249 1,239 Deferred tax assets, net 365 348 Fair value of interest rate swaps 7,645 343 Above-market lease intangible assets, net 557 611 Sales-type lease receivable 3,032 3,031 Financing right-of-use asset 1,857 1,870 Operating lease right-of-use assets 781 788 Other 386 426 $ 59,761 $ 50,337
Schedule of VIEs	The VIEs that we have identified at March 31, 2022 are summarized in the table below. Classification Carrying Amount (in thousands) Maximum Exposure to Loss (in thousands) Note receivable (term loan) $ 11,250 $ 11,250 Note receivable (revolving credit facility) $ 9,500 $ 9,500 Note receivable (term loan) $ 6,000 $ 6,000

Other Liabilities, net (Tables)

Other Liabilities, net (Tables)	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are detailed in the table below. Balance as of (Dollars in thousands) March 31, 2022 December 31, 2021 Prepaid rent $ 3,860 $ 3,791 Security deposits 4,610 4,640 Below-market lease intangibles, net 768 616 Fair value of derivatives 103 5,324 Financing lease liability 2,972 2,973 Operating lease liability 793 795 Other 446 512 $ 13,552 $ 18,651

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value, by balance sheet grouping	The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at March 31, 2022 and December 31, 2021, using level 2 inputs. March 31, 2022 December 31, 2021 (Dollars in thousands) Carrying Value Fair Value Carrying Value Fair Value Notes receivable $ 26,750 $ 26,152 $ 26,000 $ 25,869 Interest rate swap asset $ 7,645 $ 7,645 $ 343 $ 343 Interest rate swap liability $ 103 $ 103 $ 5,324 $ 5,324 Mortgage note payable (principal amount) $ 5,036 $ 4,965 $ 5,076 $ 5,129

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands, ft² in Millions	Mar. 31, 2022USD ($)ft²statereal_estate_property	Dec. 31, 2021USD ($)
Accounting Policies [Abstract]
Total real estate properties | $	$ 843,771
Number of real estate properties | real_estate_property	158
Number of properties held for investment in financing lease | real_estate_property	1
Financing lease liability | $	$ 2,972	$ 2,973
Number of states | state	34
Area of real estate property (in square feet) | ft²	3.4
Percentage leased	89.90%
Remaining lease term	7 years 7 months 6 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,178	$ 2,351	$ 5,605
Restricted cash	521	516	398
Cash, cash equivalents and restricted cash	$ 1,699	$ 2,867	$ 6,003	$ 2,892

Real Estate Properties - Additi

Real Estate Properties - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)real_estate_property	Dec. 31, 2021USD ($)
Real Estate [Abstract]
Total real estate properties | $	$ 843,771
Number of real estate properties	158
Number of properties held for investment in financing lease	1
Financing lease liability | $	$ 2,972	$ 2,973
Number of real estate properties acquired	2
Number of real estate properties increased	3
Number of property count	5

Real Estate Properties - Schedu

Real Estate Properties - Schedule of Real Estate Property Investments (Details) $ in Thousands	Mar. 31, 2022USD ($)real_estate_property
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	158
Total real estate properties | $	$ 843,771
US Healthvest
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	3
Total real estate properties | $	$ 77,964
Everest Rehabilitation
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	3
Total real estate properties | $	$ 57,100
All Others
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	152
Total real estate properties | $	$ 708,707
Texas
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	15
Total real estate properties | $	$ 136,953
Illinois
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	16
Total real estate properties | $	$ 120,172
Ohio
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	22
Total real estate properties | $	$ 77,230
Florida
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	14
Total real estate properties | $	$ 66,037
Massachusetts
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	2
Total real estate properties | $	$ 35,298
All Others
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	89
Total real estate properties | $	$ 408,081
Medical Office Building
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	65
Total real estate properties | $	$ 297,138
Acute Inpatient Behavioral
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	5
Total real estate properties | $	$ 130,367
Inpatient Rehabilitation Facilities
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	6
Total real estate properties | $	$ 127,676
Specialty Centers
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	34
Total real estate properties | $	$ 106,169
Physician Clinics
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	29
Total real estate properties | $	$ 81,988
Surgical Centers and Hospitals
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	10
Total real estate properties | $	$ 54,518
Behavioral Specialty Facilities
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	8
Total real estate properties | $	$ 30,978
Long-term Acute Care Hospitals
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	1
Total real estate properties | $	$ 14,937

Real Estate Leases - Future Min

Real Estate Leases - Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022 (nine months ending December 31)	$ 57,145
2023	72,288
2024	73,219
2025	62,603
2026	55,044
2027 and thereafter	339,736
Total	$ 660,035

Real Estate Leases - Additional

Real Estate Leases - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)real_estate_propertylease	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Concentration Risk [Line Items]
Straight line rent	$ 820	$ 838
Real estate investment property, net	$ 699,770		$ 701,029
Number of real estate properties | real_estate_property	158
Number of properties held for investment in financing lease | real_estate_property	1
Financing lease liability	$ 2,972		$ 2,973
Interest income	$ 100	$ 100
Number of operating leases | lease	4
Number of finance leases | lease	1
Four Real Estate Property
Concentration Risk [Line Items]
Real estate investment property, net	$ 25,200
Number of real estate properties | real_estate_property	4

Real Estate Leases - Lease Rece

Real Estate Leases - Lease Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2022 (nine months ended December 31)	$ 246
2023	336
2024	346
2025	356
2026	367
2027 and thereafter	5,587
Total undiscounted lease receivable	7,238
Discount	(4,206)
Lease receivable	$ 3,032	$ 3,031

Real Estate Leases - Future Lea

Real Estate Leases - Future Lease Payments Under Non-prepaid Ground Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating
2022 (nine months ended December 31)	$ 31
2023	42
2024	43
2025	44
2026	44
2027 and thereafter	1,193
Total undiscounted lease payments	1,397
Discount	(604)
Lease liabilities	793	$ 795
Financing
2022 (nine months ended December 31)	94
2023	125
2024	138
2025	138
2026	138
2027 and thereafter	5,483
Total undiscounted lease payments	6,116
Discount	(3,144)
Lease liabilities	$ 2,972	$ 2,973

Real Estate Leases - Ground Lea

Real Estate Leases - Ground Leases (Details)	Mar. 31, 2022	Mar. 31, 2021
Operating leases:
Weighted-average remaining lease term in years (including renewal options)	36 years 8 months 23 days	37 years 11 months 19 days
Weighted-average discount rate	4.00%	4.00%
Financing leases:
Weighted-average remaining lease term in years (including renewal options)	36 years 9 months
Weighted-average discount rate	4.10%

Real Estate Acquisitions - Addi

Real Estate Acquisitions - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)real_estate_property
Business Acquisition [Line Items]
Number of real estate properties acquired | real_estate_property	2
Acquisitions Of Properties
Business Acquisition [Line Items]
Percentage of properties that were leased at acquisition	100.00%
Pro forma information, revenue of acquiree since acquisition date, actual	$ 45
Pro forma information, loss of acquiree since acquisition date, actual	5
Transaction costs	$ 100

Real Estate Acquisitions - Real

Real Estate Acquisitions - Real Estate Acquisitions (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)ft²
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Square footage (in square feet) | ft²	3,400,000
Acquisitions Of Properties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 5,838
Cash Consideration	5,845
Real Estate	6,178
Other	$ (333)
Square footage (in square feet) | ft²	30,315
Acquisitions Of Properties | Toledo, OH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 2,606
Cash Consideration	2,621
Real Estate	2,735
Other	$ (114)
Square footage (in square feet) | ft²	17,465
Acquisitions Of Properties | Fremont, NE
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 3,232
Cash Consideration	3,224
Real Estate	3,443
Other	$ (219)
Square footage (in square feet) | ft²	12,850

Real Estate Acquisitions - Asse

Real Estate Acquisitions - Assets Acquired and Liabilities Assumed (Details) - Series of Individually Immaterial Asset Acquisitions $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Business Acquisition [Line Items]
Land and land improvements	$ 1,123
Building and building improvements	3,868
Intangibles:
Below-market lease intangibles	$ (194)
Below market lease useful life (in years)	6 years 1 month 6 days
Total intangibles	$ 993
Accounts payable, accrued liabilities and other liabilities assumed	(97)
Prorated rent, interest and operating expense reimbursement amounts collected	(42)
Total cash consideration	5,845
At-market lease intangibles
Intangibles:
Lease intangibles	$ 1,187
Intangibles useful life (in years)	4 years 6 months
Land and land improvements
Business Acquisition [Line Items]
Estimated useful life (in years)	6 years 2 months 12 days
Building and building improvements
Business Acquisition [Line Items]
Estimated useful life (in years)	20 years 6 months

Debt, net - Schedule of Debt (D

Debt, net - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt, net	$ 269,670	$ 265,625
Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	250,000
Mortgage Note Payable, net
Debt Instrument [Line Items]
Debt, net	4,995	5,029
Revolving Credit Facility | Line of Credit | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	16,000	12,000
A-2 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	49,833	49,813
A-3 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	74,518	74,487
A-4 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	$ 124,324	$ 124,296

Debt, net - Narrative (Details)

Debt, net - Narrative (Details)	Mar. 19, 2021USD ($)option	Mar. 29, 2019	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Line of Credit Facility [Line Items]
Amount outstanding			$ 269,670,000	$ 265,625,000
Third Amended And Restated Credit Facility | Term Loan
Line of Credit Facility [Line Items]
Amount outstanding			$ 250,000,000
Weighted average interest rate percentage			3.79%
Third Amended And Restated Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Term Loan
Line of Credit Facility [Line Items]
Variable rate percentage	1.45%
Third Amended And Restated Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Term Loan
Line of Credit Facility [Line Items]
Variable rate percentage	2.30%
Third Amended And Restated Credit Facility | Base Rate | Minimum | Term Loan
Line of Credit Facility [Line Items]
Variable rate percentage	0.45%
Third Amended And Restated Credit Facility | Base Rate | Maximum | Term Loan
Line of Credit Facility [Line Items]
Variable rate percentage	1.30%
Third Amended And Restated Credit Facility | Credit Facility, Accordion Feature
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 600,000,000
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 150,000,000
Number of options to extend | option	1
Length of extension	12 months
Amount outstanding			$ 16,000,000	12,000,000
Weighted average interest rate percentage			3.00%
Remaining borrowing capacity			$ 134,000,000
Third Amended And Restated Credit Facility | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Line of Credit
Line of Credit Facility [Line Items]
Variable rate percentage		1.25%
Third Amended And Restated Credit Facility | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Line of Credit
Line of Credit Facility [Line Items]
Variable rate percentage		1.90%
Third Amended And Restated Credit Facility | Revolving Credit Facility | Base Rate | Minimum | Line of Credit
Line of Credit Facility [Line Items]
Variable rate percentage		0.25%
Third Amended And Restated Credit Facility | Revolving Credit Facility | Base Rate | Maximum | Line of Credit
Line of Credit Facility [Line Items]
Variable rate percentage		0.90%
Third Amended And Restated Credit Facility | Term Loan | Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 250,000,000
Third Amended And Restated Credit Facility | A-2 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Debt term	7 years
Face amount	$ 50,000,000
Amount outstanding			49,833,000	49,813,000
Third Amended And Restated Credit Facility | A-3 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Debt term	7 years
Face amount	$ 75,000,000
Amount outstanding			74,518,000	74,487,000
Third Amended And Restated Credit Facility | A-4 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Debt term	7 years
Face amount	$ 125,000,000
Amount outstanding			$ 124,324,000	$ 124,296,000
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 1 | Line of Credit
Line of Credit Facility [Line Items]
Unused borrowing commitment fee percentage	0.20%
Percentage of borrowing capacity outstanding	33.30%
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 2 | Line of Credit
Line of Credit Facility [Line Items]
Unused borrowing commitment fee percentage	0.25%
Percentage of borrowing capacity outstanding	33.30%

Derivative Financial Instrume_3

Derivative Financial Instruments - Narrative (Details)	3 Months Ended
	Mar. 31, 2022USD ($)derivative_instrument
Derivative [Line Items]
Cash flow hedges reclassified to interest expense	$ 5,200
Cash Flow Hedging | Interest Rate Contract
Derivative [Line Items]
Number outstanding interest rate derivatives | derivative_instrument	12
Notional amount	$ 250,000,000

Derivative Financial Instrume_4

Derivative Financial Instruments - Fair Value Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Interest rate swap asset	$ 7,645	$ 343
Interest rate swap liability	103	5,324
Cash Flow Hedging | Interest rate swaps | Designated as Hedging Instrument | Other assets, net
Derivatives, Fair Value [Line Items]
Interest rate swap asset	7,645	343
Cash Flow Hedging | Interest rate swaps | Designated as Hedging Instrument | Other liabilities, net
Derivatives, Fair Value [Line Items]
Interest rate swap liability	$ 103	$ 5,324

Derivative Financial Instrume_5

Derivative Financial Instruments - Cash Flow Hedging (Details) - Interest Rate Contract - Cash Flow Hedging - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Amount of unrealized gain recognized in OCI on derivatives	$ 11,407	$ 2,803
Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of loss reclassified from AOCI into interest expense	1,115	932
Total interest expense presented in the Condensed Consolidated Statements of Income in which the effects of the cash flow hedges are recorded	$ 2,626	$ 2,229

Derivative Financial Instrume_6

Derivative Financial Instruments - Offsetting of Derivative Assets and Liability (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Derivative Asset [Abstract]
Gross Amounts of Recognized Assets	$ 7,645	$ 343
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Net Amounts of Assets in the Condensed Consolidated Balance Sheets	7,645	343
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Financial Instruments	(103)	(247)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Net Amount	0	0
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Cash Collateral Received	7,542	96
Derivative Liability [Abstract]
Gross Amounts of Recognized Liabilities	(103)	(5,324)
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets	(103)	(5,324)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Financial Instruments	103	247
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Cash Collateral Received	0	0
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets, Net Amount	$ 0	$ (5,077)

Stockholders' Equity - Reconcil

Stockholders' Equity - Reconciliation of Common Stock (Details) - shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period (in shares)	24,983	23,888
Issuance of common stock (in shares)	0	823
Restricted stock-based awards (in shares)	92	273
Restricted stock forfeited (in shares)	(3)	(1)
Balance, end of period (in shares)	25,072	24,983

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - At The Market Offering Program - Common Stock shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)shares
Subsidiary, Sale of Stock [Line Items]
Value of shares authorized | $	$ 360
Shares available for issuance (in shares) | shares	101

Net Income Per Common Share (De

Net Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net income	$ 5,524	$ 5,315
Participating securities' share in earnings	(658)	(538)
Net income, less participating securities' share in earnings	$ 4,866	$ 4,777
Weighted average Common Shares outstanding
Weighted average Common Shares outstanding (in shares)	25,060	24,053
Unvested restricted shares (in shares)	(1,490)	(1,244)
Weighted average Common Shares outstanding–Basic (in shares)	23,570	22,809
Dilutive potential common share (in shares)	0	0
Weighted average Common Shares outstanding –Diluted (in shares)	23,570	22,809
Basic Net Income per Common Share (in dollars per share)	$ 0.21	$ 0.21
Diluted Net Income per Common Share (in dollars per share)	$ 0.21	$ 0.21

Stock Incentive Plan - Restrict

Stock Incentive Plan - Restricted Stock Activity (Details) - 2014 Incentive Plan - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restricted Common Stock
Stock-based awards:
Stock-based awards, beginning of period (in shares)	1,416	1,165
Granted (in shares)	92	93
Vested (in shares)	(5)	0
Forfeited (in shares)	(1)	0
Stock-based awards, end of period (in shares)	1,502	1,258
Amortization expense	$ 2,122	$ 1,558
Stock in lieu of compensation
Stock-based awards:
Granted (in shares)	44	44
Stock awards
Stock-based awards:
Granted (in shares)	48	49

Other Assets, net - Other Asset

Other Assets, net - Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Notes receivable	$ 26,750	$ 26,000
Accounts and interest receivable	2,741	2,116
Straight-line rent receivable	12,806	11,968
Prepaid assets	749	701
Deferred financing costs, net	843	896
Leasing commissions, net	1,249	1,239
Deferred tax assets, net	365	348
Fair value of interest rate swaps	7,645	343
Above-market lease intangible assets, net	557	611
Lease receivable	3,032	3,031
Financing right-of-use asset	1,857	1,870
Operating lease right-of-use assets	781	788
Other	386	426
Other assets, net	$ 59,761	$ 50,337

Other Assets, net - Narrative (

Other Assets, net - Narrative (Details)	3 Months Ended
	Mar. 31, 2022USD ($)hospital	Dec. 31, 2021USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 26,750,000	$ 26,000,000
Note receivable (term loan) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 11,250,000
Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable interest rate	9.00%
Additional funding	$ 5,000,000
Non-cash interest rate	3.00%
Note receivable (term loan) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 6,000,000
Note receivable (revolving credit facility) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 9,500,000
Geriatric Behavioral Hospital
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	6
Revolving Credit Facility | Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable interest rate	9.00%
Note receivable (term loan) | Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 11,300,000	$ 12,000,000
Payment received	$ 250,000
Note receivable interest rate	9.00%
Note receivable (term loan) | Long-Term Acute Care Hospitals
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	7
Note receivable (term loan) | Inpatient Rehabilitation Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	1

Other Assets, net - VIEs (Detai

Other Assets, net - VIEs (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Carrying amount	$ 26,750	$ 26,000
Variable Interest Entity, Not Primary Beneficiary | Note receivable (term loan)
Variable Interest Entity [Line Items]
Carrying amount	11,250
Maximum exposure to loss	11,250
Variable Interest Entity, Not Primary Beneficiary | Note receivable (revolving credit facility)
Variable Interest Entity [Line Items]
Carrying amount	9,500
Maximum exposure to loss	9,500
Variable Interest Entity, Not Primary Beneficiary | Note receivable (term loan)
Variable Interest Entity [Line Items]
Carrying amount	6,000
Maximum exposure to loss	$ 6,000

Other Liabilities, net (Details

Other Liabilities, net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Prepaid rent	$ 3,860	$ 3,791
Security deposits	4,610	4,640
Below-market lease intangibles, net	768	616
Fair value of derivatives	103	5,324
Financing lease liability	2,972	2,973
Operating lease liability	793	795
Other	446	512
Other liabilities, net	$ 13,552	$ 18,651

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	$ 26,750	$ 26,000
Interest rate swap asset	7,645	343
Interest rate swap liability	103	5,324
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	26,750	26,000
Mortgage note payable (principal amount)	5,036	5,076
Carrying Value | Interest rate swap liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap asset	7,645	343
Interest rate swap liability	103	5,324
Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	26,152	25,869
Mortgage note payable (principal amount)	4,965	5,129
Fair Value | Interest rate swap liability | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap asset	7,645	343
Interest rate swap liability	$ 103	$ 5,324

Subsequent Events (Details)

Subsequent Events (Details)	Apr. 28, 2022$ / shares
Subsequent Event
Subsequent Event [Line Items]
Dividend declared (in dollars per share)	$ 0.44